Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
SwedishAmerican Hospital
352
mi
from 43215
Rockford, IL
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
SwedishAmerican Hospital
352
mi
from 43215
Rockford, IL
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas
784
mi
from 43215
Wichita, KA
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas
784
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinic
799
mi
from 43215
New Orleans, LA
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinic
799
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Greater Baltimore Medical Center
342
mi
from 43215
Baltimore, MD
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Greater Baltimore Medical Center
342
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
St. Joseph Mercy Hospital Ann Arbor
255
mi
from 43215
Ann Arbor, MI
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
St. Joseph Mercy Hospital Ann Arbor
255
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
West Michigan Cancer Center
210
mi
from 43215
Kalamazoo, MI
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
West Michigan Cancer Center
210
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Metro-Minnesota CCOP
627
mi
from 43215
Saint Louis Park, MN
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Metro-Minnesota CCOP
627
mi
from 43215
Saint Louis Park, MN
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Ocean Medical Center
469
mi
from 43215
Brick, NJ
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Ocean Medical Center
469
mi
from 43215
Brick, NJ
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Morristown Memorial Hospital
453
mi
from 43215
Morristown, NJ
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Morristown Memorial Hospital
453
mi
from 43215
Morristown, NJ
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
The Cancer Institute of New Jersey
453
mi
from 43215
New Brunswick, NJ
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
The Cancer Institute of New Jersey
453
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Riverview Medical Center
473
mi
from 43215
Red Bank, NJ
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Riverview Medical Center
473
mi
from 43215
Red Bank, NJ
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Aultman Hospital
102
mi
from 43215
Canton, OH
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Aultman Hospital
102
mi
from 43215
Canton, OH
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Abington Memorial Hospital
417
mi
from 43215
Abington, PA
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Abington Memorial Hospital
417
mi
from 43215
Abington, PA
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Hematology & Oncology of NEPA
mi
from 43215
Dunmore, PA
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Hematology & Oncology of NEPA
mi
from 43215
Dunmore, PA
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Lancaster General Hospital
353
mi
from 43215
Lancaster, PA
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Lancaster General Hospital
353
mi
from 43215
Lancaster, PA
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Central PA Hematology & Medical Oncology Associaties
mi
from 43215
Lemoyne, PA
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Central PA Hematology & Medical Oncology Associaties
mi
from 43215
Lemoyne, PA
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Albert Einstein Cancer Center
416
mi
from 43215
Philadelphia, PA
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Albert Einstein Cancer Center
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Reading Hospital and Medical Center
376
mi
from 43215
Reading, PA
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Reading Hospital and Medical Center
376
mi
from 43215
Reading, PA
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Mount Nittany Medical Center
275
mi
from 43215
State College, PA
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Mount Nittany Medical Center
275
mi
from 43215
State College, PA
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Sanford Clinic
747
mi
from 43215
Sioux Falls, SD
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Sanford Clinic
747
mi
from 43215
Sioux Falls, SD
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Meharry Medical College
332
mi
from 43215
Nashville, TN
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Meharry Medical College
332
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Charleston Area Medical Center
137
mi
from 43215
Charleston, WV
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Charleston Area Medical Center
137
mi
from 43215
Charleston, WV
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
St. Vincent Hospital
404
mi
from 43215
Green Bay, WI
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
St. Vincent Hospital
404
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Gundersen Lutheran
499
mi
from 43215
La Crosse, WI
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Gundersen Lutheran
499
mi
from 43215
La Crosse, WI
Click here to add this to my saved trials
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Regional Cancer Center
mi
from 43215
Waukesha, WI
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Regional Cancer Center
mi
from 43215
Waukesha, WI
Click here to add this to my saved trials
Eniluracil Hand Foot Syndrome
A Pilot Study of Eniluracil Containing Ointment for Prevention of Hand Foot Syndrome (HRS) Following Capecitabine (Xeloda)
Status: Enrolling
Updated:  12/31/1969
Clinical Trials Research Unit, West Virginia University
163
mi
from 43215
Morgantown, WV
Eniluracil Hand Foot Syndrome
A Pilot Study of Eniluracil Containing Ointment for Prevention of Hand Foot Syndrome (HRS) Following Capecitabine (Xeloda)
Status: Enrolling
Updated: 12/31/1969
Clinical Trials Research Unit, West Virginia University
163
mi
from 43215
Morgantown, WV
Click here to add this to my saved trials
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer
Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rebecca and John Moores UCSD Cancer Center
1950
mi
from 43215
La Jolla, CA
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer
Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rebecca and John Moores UCSD Cancer Center
1950
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
Using Virtual Reality (VR) Models for Preoperative Planning - JWCI
Using Virtual Reality (VR) Models for Preoperative Planning - JWCI
Status: Enrolling
Updated:  12/31/1969
John Wayne Cancer Institute @ Providence St Johns Health Center
1986
mi
from 43215
Santa Monica, CA
Using Virtual Reality (VR) Models for Preoperative Planning - JWCI
Using Virtual Reality (VR) Models for Preoperative Planning - JWCI
Status: Enrolling
Updated: 12/31/1969
John Wayne Cancer Institute @ Providence St Johns Health Center
1986
mi
from 43215
Santa Monica, CA
Click here to add this to my saved trials
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from 43215
Vallejo, CA
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from 43215
Vallejo, CA
Click here to add this to my saved trials
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from 43215
Greenville, NC
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from 43215
Greenville, NC
Click here to add this to my saved trials
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from 43215
Scranton, PA
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from 43215
Scranton, PA
Click here to add this to my saved trials
Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis
Comparison of the Healing of Chemotherapy-Induced Oral Mucositis Using Oral Defense Toothpaste Versus Crest Toothpaste and Magic Mouth Rinse
Status: Enrolling
Updated:  12/31/1969
Summit Cancer Centers
1778
mi
from 43215
Spokane, WA
Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis
Comparison of the Healing of Chemotherapy-Induced Oral Mucositis Using Oral Defense Toothpaste Versus Crest Toothpaste and Magic Mouth Rinse
Status: Enrolling
Updated: 12/31/1969
Summit Cancer Centers
1778
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
274
mi
from 43215
Chicago, IL
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Status: Enrolling
Updated:  12/31/1969
Northwestern University- Lake Forest Hospital
296
mi
from 43215
Lake Forest, IL
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Status: Enrolling
Updated: 12/31/1969
Northwestern University- Lake Forest Hospital
296
mi
from 43215
Lake Forest, IL
Click here to add this to my saved trials
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
A Phase II Evaluation of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Gynecologic Oncology Group
416
mi
from 43215
Philadelphia, PA
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
A Phase II Evaluation of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Gynecologic Oncology Group
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1666
mi
from 43215
Peoria, AZ
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1666
mi
from 43215
Peoria, AZ
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2039
mi
from 43215
Sacramento, CA
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2039
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
323
mi
from 43215
Bethesda, MD
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
323
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
643
mi
from 43215
Boston, MA
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
331
mi
from 43215
Nashville, TN
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials